Chronic Refractory Cough Cohort (COCO) (H-41623)

The purpose of this study is to evaluate different doses of the investigational study drug nemiralisib inhalation powder inhaled through the ELLIPTA™ inhaler to see if it is safe and how well it works in improving lung function and in treating an acute exacerbation (or sudden worsening) of chronic obstructive pulmonary disease (COPD.) We want to find out what effects, good or bad, it has on people with COPD. In addition, we want to find out how much of the study drug gets into the blood stream and how long the body takes to get rid of it.